Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - capmatinib dihydrochloride monohydrate eqv capmatinib - tablet, film coated - capmatinib dihydrochloride monohydrate eqv capmatinib 150mg

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - capmatinib dihydrochloride monohydrate eqv capmatinib - tablet, film coated - capmatinib dihydrochloride monohydrate eqv capmatinib 200mg

Israel - English - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 150 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.

Israel - English - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 200 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - capmatinib (capmatinib hydrochloride) - tablet - 150mg - capmatinib (capmatinib hydrochloride) 150mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - capmatinib (capmatinib hydrochloride) - tablet - 200mg - capmatinib (capmatinib hydrochloride) 200mg

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinoma, non-small-cell lung - antineoplastic agents - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.